
- Industry news
Industry news
- Category news
- Reports
- Key trends
- Multimedia
Multimedia
- Journal
- Events
- Suppliers
Suppliers
- Home
- Industry news
Industry news
- Category news
- Reports
- Key trends
- Multimedia
Multimedia
- Events
- Suppliers
Suppliers
More than 50 published clinical studies have been conducted on Chr. Hansen's BB-12 Bifidobacterium, LA-5 Lactobacillus acidophilus and L. casei 431.
More than 50 published clinical studies have been conducted on Chr. Hansen's BB-12 Bifidobacterium, LA-5 Lactobacillus acidophilus and L. casei 431. In studies evaluating these specific strains, researchers report enhanced intestinal well-being and positive effects on diarrhea, antibiotic-associated diarrhea, traveler's diarrhea and constipation, as well as enhanced immunity and positive effect on the skin disorder, atopic dermatitis. Proprietary encapsulation and tableting technology allows the probiotic bacteria to survive passage through the stomach and reach the small intestine. The company manufactures its probiotics using GMP and pharmaceutical standards.
All content and features on this website are copyrighted with all rights reserved. The full details can be found in our privacy statement
Upcoming webinars

The science of HMOs – A novonesis webinar featuring new clinical findings and ESPGHAN highlights
Novonesis
Register now

From boosters to companions: GLP-1 in Food, Beverages and Supplements
Rousselot
Register now

Top Nutrition Trends 2027
Nutrition Insight
Register now
All upcoming webinars
Subscribe to our newsletters
By continuing to browse our site you agree to our Privacy Statement








